Overview

Open-label Trial of Leukine in Active Crohn's Disease

Status:
Terminated
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to establish a safety profile sargramostim administered in 8 week cycles to adult patients with active Crohn's disease.
Phase:
Phase 2
Details
Lead Sponsor:
Genzyme, a Sanofi Company
Treatments:
Molgramostim
Sargramostim